Abstract: A method of treatment for human patients with an acquired hypercoagulable state or acquired protein C deficiency associated with sepsis, purpura fulminans, meningococcal sepsis, bone marrow and other transplantations, severe burns, pregnancy, major surgery, severe trauma, or ARDS, which comprises administering activated protein C providing a highly selective therapeutic agent with a low potential for causing bleeding complications.
Type:
Grant
Filed:
May 10, 2000
Date of Patent:
December 3, 2002
Assignee:
Eli Lilly and Company
Inventors:
Brian William Grinnell, Daniel Lawrence Hartman, Sau-Chi Betty Yan